What indicators need to be checked regularly when taking ruxolitinib tablets?

When taking ruxolitinib tablets (JAKAVI), patients need to regularly check the following important indicators to ensure the safety and effectiveness of the treatment:

1. Routine blood examination: Ruxolitinib may affect the hematopoietic function of the bone marrow, resulting in a decrease in the number of blood cells. It is very important to check the blood routine regularly, especially the number of white blood cells, red blood cells and platelets. If blood abnormalities are found, drug dosage may need to be adjusted or treatment suspended. A decrease in white blood cells and platelets may increase the risk of infection or bleeding.

2. Liver function testing: Ruxolitinib is mainly metabolized in the liver, so patients need to regularly check liver enzymes (such as ALT, AST) and total bilirubin levels to monitor liver function. If liver function abnormalities are found, the dose may need to be reduced or the drug discontinued. Patients with liver dysfunction may cause the drug to accumulate in the body, increasing the risk of side effects.

3. Renal function test: Although ruxolitinib is mainly metabolized by the liver, patients with renal insufficiency still require special attention. Patients should have their serum creatinine and urea nitrogen levels checked regularly to ensure normal kidney function. Poor renal function may affect drug clearance, causing higher drug concentrations and increasing the risk of side effects.

4. Monitoring of blood lipid levels: Long-term use of ruxolitinib may lead to elevated cholesterol and triglyceride levels, increasing the risk of cardiovascular disease. Regular testing of lipid levels, especially during treatment, can help identify and manage potential cardiovascular problems in a timely manner. If lipid levels are abnormal, intervention may be needed, such as dietary modification or medication.

5. Infection monitoring: Because ruxolitinib has a certain inhibitory effect on the immune system, patients are susceptible to infection during use. Regular monitoring is required for signs of infection, especially upper respiratory tract infections, urinary tract infections, etc. If there are symptoms of infection, it is important to treat them promptly.

Through these regular inspections, possible side effects of ruxolitinib can be effectively managed, the safety of the treatment process can be ensured, and necessary adjustments can be made in a timely manner.